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ABSTRACT
A RANDOMISED CONTROLLED TRIAL OF MGSO4 THERAPY FOR 24 HOURS VERSUS EARLY
CESSATION IN PATIENTS WITH SEVERE PREECLAMPSIA
Dr Affendi Yunus
MMed Obstetric & Gynaecology
Department of Obstetric & Gynaecology
School of Medical Sciences, Universiti Sains Malaysia
Health Campus, 16150 Kelantan, Malaysia
Introduction:
Magnesium sulphate has been shown to be the optimal anticonvulsant in
preventing the recurrence of seizures in eclampsia and in seizure prophylaxis
in preeclampsia. Traditionally, seizure prophylaxis has been administered
before delivery and continued postpartum for an arbitrary time, usually 24
hours.
 Objectives:
The primary objectives of this study were to evaluate the safety and
effectiveness of using clinical parameters to signal cessation of postpartum
magnesium sulphate therapy among patients with Severe Preeclampsia.
Methodology:
A randomized trial of postpartum magnesium sulphate therapy was conducted in
HRPZII, Kota Bharu and HUSM, Kubang Kerian from December 2009 to September
2010. The control group received 24 hours of therapy, and the intervention
group received therapy until fulfilled clinical criteria for discontinuation
of seizure prophylaxis. The Independent t test, Chi-square test, and Fisher’s
exact test were used for analysis of data. A probability value of <0.05 was
considered statistically significant.
Results:
 There were 52 patients in the control group and 50 patients in the
intervention group.  The intervention group had a significantly shorter
duration of therapy (p< 0.05). There were no differences in mean booking BMI,
weight on admission, systolic blood pressure and platelet level between two
groups. However there were significance differences in mean age of the
patients, delivery gestational age, diastolic blood pressure and uric acid
level between two groups. There was no patient in this study had eclampsia or
required the reinitiation of therapy.
Conclusions:
Clinical parameters can be used effectively and safe to shorten the duration
of postpartum magnesium sulphate therapy in patients with severe preeclampsia.
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KAJIAN CUBAAN RAWAK TERKAWAL PENGGUNAAN MAGNESIUM SULPHATE SELAMA 24
JAM BERBANDING PEMBERHENTIAN AWAL BAGI PESAKIT PREECLAMPSIA 
Pengenalan:
Magnesium sulphate telah terbukti sebagai antikonvulsi yang optimum di
dalam pencegahan sawan yang berulang bagi eclampsia dan juga bertindak
sebagai pencegah sawan bagi preeclampsia. Sebelum ini, magnesium
sulphate yang digunakan sebagai pencegah sawan sebelum bersalin akan
terus digunakan selepas bersalin sehingga ke suatu waktu, biasanya 
hingga 24 jam selepas bersalin. 
Objektif:
Tujuan utama penyelidikan ini adalah untuk menilai keberkesanan dan
keselamatan penggunaan kriteria klinikal sebagai petanda untuk
pemberhentian magnesium sulphate selepas bersalin bagi pesakit
preeclampsia.
Kaedah:
Penyelidikan secara kajian rawak terkawal penggunaan magnesium sulphate
selepas bersalin telah dijalankan di HRPZII, Kota Bharu dan HUSM,
Kubang Kerian bermula pada December 2009 sehingga September 2010.
Pesakit di dalam kumpulan kawalan menerima rawatan sehingga 24 jam
selepas bersalin. Pesakit di dalam kumpulan intervensi menerima rawatan
sehingga memenuhi kriteria klinikal untuk pemberhentian rawatan. Kaedah
“Independent t test, Chi-square test dan Fisher exact test” digunakan
untuk menganalisa data. Kebarangkalian nilai < 0.05 dikira sebagai
‘significant’ secara statistik.
Keputusan:
Seramai 52 orang pesakit telah menyertai kumpulan kawalan dan 50 orang
telah menyertai kumpulan intervensi. Didapati kumpulan intervensi telah
menerima rawatan magnesium sulphate dengan kadar yang lebih singkat (p<
0.05). Tiada perbezaan dari segi purata indeks jisim tubuh, berat
badan, tekanan darah sistolik and  paras platelet diantara pesakit
kedua-dua kumpulan kajian. Walaubagaimanapun, terdapat perbezaan dari
segi purata umur pesakit, gestasi semasa kelahiran , tekanan darah
diastolik, dan paras uric acid diantara pesakit kedua-dua kumpulan
kajian. Tiada pesakit yang menyertai kajian ini mendapat eclampsia atau
memerlukan rawatan magnesium sulphate semula setelah diberhentikan
sebelum ini. 
Kesimpulan:
Kriteria klinikal boleh digunakan dengan berkesan dan selamat sebagai
petanda untuk mengurangkan jangkamasa penggunaan magnesium sulphate
selepas bersalin bagi pesakit preeclampsia.
ABSTRACT
A RANDOMISED CONTROLLED TRIAL OF MGSO4 THERAPY FOR 24 HOURS VERSUS
EARLY CESSATION IN PATIENTS WITH SEVERE PREECLAMPSIA
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Introduction:
Magnesium sulphate has been shown to be the optimal anticonvulsant in
preventing the recurrence of seizures in eclampsia and in seizure
prophylaxis in preeclampsia. Traditionally, seizure prophylaxis has
been administered before delivery and continued postpartum for an
arbitrary time, usually 24 hours.
 Objectives:
The primary objectives of this study were to evaluate the safety and
effectiveness of using clinical parameters to signal cessation of
postpartum magnesium sulphate therapy among patients with Severe
Preeclampsia.
Methodology:
A randomized trial of postpartum magnesium sulphate therapy was
conducted in HRPZII, Kota Bharu and HUSM, Kubang Kerian from December
2009 to September 2010. The control group received 24 hours of therapy,
and the intervention group received therapy until fulfilled clinical
criteria for discontinuation of seizure prophylaxis. The Independent t
test, Chi-square test, and Fisher’s exact test were used for analysis
of data. A probability value of <0.05 was considered statistically
significant.
Results:
 There were 52 patients in the control group and 50 patients in the
intervention group.  The intervention group had a significantly shorter
duration of therapy (p< 0.05). There were no differences in mean
booking BMI, weight on admission, systolic blood pressure and platelet
level between two groups. However there were significance differences
in mean age of the patients, delivery gestational age, diastolic blood
pressure and uric acid level between two groups. There was no patient
in this study had eclampsia or required the reinitiation of therapy.
Conclusions:
Clinical parameters can be used effectively and safe to shorten the
duration of postpartum magnesium sulphate therapy in patients with
severe preeclampsia.
1CHAPTER ONE: INTRODUCTION
Background of the study
Hypertensive disorders of pregnancy (HDP) are the most common medical
complications of pregnancy and are important causes of maternal and
perinatal morbidity and mortality worldwide. HDP accounts for 7-10% of
admission to public hospital obstetrics units in the country (CEMD
Malaysia, 1997-2000). The prevalence of HDP in Malaysia is 23.3 per
1000 live births. HDP is the third leading cause of maternal mortality
in Malaysia – 14.2%. The immediate associations with death were
eclampsia, cardiopulmonary complications, cerebral hemorrhage, severe
preeclampsia and disseminated intravascular coagulopathy (DIVC) (CEMD
Malaysia, 1997-2000).
Hypertensive disease complicates 5–8% of pregnancies in the United
States and ranks second only to thromboembolic disease as the leading
cause of maternal mortality (ACOG, 2002). The goal of treatment in
preeclampsia is to prevent eclamptic seizures and their resultant
morbidity whereas, in eclamptic patients, the goal is to prevent
recurrent seizures. Magnesium sulphate has been shown to be the optimal
anticonvulsant for this indication (Collaborative Eclampsia Trial,
1995). 
Traditionally, seizure prophylaxis has been administered before
delivery and continued postpartum for an arbitrary time, usually 24
hours. Some investigators have used individual patient parameters to
determine the duration of postpartum seizure prophylaxis. Ascarelli et
al (1998) used a combination of patient signs (blood pressure, urinary
output), symptoms (headache, visual changes), and laboratory
assessments (proteinuria determination by dipstick analysis) to guide
postpartum magnesium sulphate duration. In 2003, Isler et al used
individual patient clinical parameters to signal cessation of
postpartum seizure prophylaxis for the spectrum of pregnancy related
hypertensive disorders. The conclusion of their study was clinical
criteria can be used successfully to shorten the duration of postpartum
magnesium sulphate therapy in patients with pregnancy related
disorders. Fontenot et al (2004) used the onset of diuresis in the
determination of the duration of postpartum magnesium sulphate therapy
among patients with severe preeclampsia. They found that the use of
diuresis in the postpartum period as determinant clinical parameter for
discontinuation of magnesium sulphate in patients with severe
preeclampsia was associated with no untoward outcomes or need for the
re-initiation of treatment (Fontenot et al, 2004).
The purpose of this study was to determine if the duration of
postpartum magnesium sulphate as a seizure prophylaxis administered in
patients with the spectrum of hypertensive disorders of pregnancy
(including severe preeclampsia and chronic hypertension with
superimposed preeclampsia) could be guided by clinical parameters.
1.2 Justification, rationale and benefits of the study
The use of magnesium sulphate for seizure prophylaxis has been shown to
be efficacious in women with severe preeclampsia. The optimal duration
of magnesium therapy has not been determined.  Magnesium sulphate
therapy is often arbitrarily given for 24 hours after delivery,
depending on severity of disease.  The use of magnesium sulphate
therapy is not without complication. Maternal morbidity and mortality
1can occur because of magnesium overdose.
Current theories regarding the pathogenesis of preeclampsia postulate
the disorder commences with abnormal placental implantation. However,
the clinical manifestations
of the disease result from widespread vasoconstriction.  Eclampsia is
believed to be caused by ischemia from cerebral under-perfusion
resulting from this vasoconstriction, although some cases of eclampsia
may be caused by hypertensive encephalopathy from
cerebral over-perfusion. This study suggests that an individual
clinical parameter can be used as a guide to stop the postpartum
magnesium sulphate therapy. 
The rationale and expected benefits of the study include:
To evaluate the safety and effectiveness of using clinical parameters
to signal cessation of postpartum magnesium sulphate in patients with
severe preeclampsia.
To compare the outcomes of MgSO4 therapy as postpartum seizures
prophylaxis following conventional 24 hours and early cessation based
on clinical parameters.
To determine the optimal duration of MgSO4 therapy in pregnant women
with severe preeclampsia.
No local published data available. As far as we are aware there are no
local or national data using clinical parameter to signal cessation of
postpartum magnesium sulphate therapy.
The conceptual framework
Pregnant women with hypertension can be broadly divided into three
categories: chronic hypertension, non-proteinuric hypertension
(sometimes known as pregnancy-induced hypertension) or preeclampsia. To
distinguish between these categories is clinically useful as their
management and likely prognosis are disparate. The key signs of
preeclampsia are hypertension and proteinuria and these are used to
define the disease. These are responses to end-organ damage and they
are not always the most important nor fundamental aspects of the
syndrome, but are used as they are easy to measure. 
Although most women who get preeclampsia do not have risk factors, a
significant proportion (>1 in 3) will. Taking a careful history will
allow risk assessment. The
National Institute of Clinical Excellence (NICE, 2003) antenatal
guidelines suggests this is an important part of clinical management
and recommends that at first contact a woman’s level of risk for
preeclampsia should be evaluated so that a plan for her subsequent
schedule of antenatal appointments can be formulated. These guidelines
have indicated the following as risk factors for developing
preeclampsia; nulliparity, age 40 or older, a family history of
preeclampsia (e.g. preeclampsia in a mother or sister), a previous
history of preeclampsia, a body mass index (BMI) at or above 35 at
first contact, a multiple pregnancy or preexisting vascular disease
(e.g., hypertension or Diabetes). 
.
1Figure 1 Conceptual framework showing possible factors influencing the
disease
Background of the study area and patient recruitment
Kelantan is located at the northeast part of Peninsular Malaysia facing
the South China Sea. Also well known as “Serambi Mekah”, the state is
divided into 10 administrative districts namely Kota Bharu, Tumpat,
Pasir Mas, Bachok, Pasir Puteh, Machang, Kuala Krai, Gua Musang, Tanah
Merah and Jeli.
Kota Bharu is the state capital of Kelantan. The name means ‘new city’
or ‘new castle/fort’ in Bahasa Malaysia. The total population of Kota
Bharu district is 452,131 (30.8% of the total population of Kelantan)
with 226,930 females and 225,201 males. Most residents work in
government and private agencies, some are involved in agricultural work
such as farming and fishing and the rest are doing small scale business
. 
Kota Bharu was established by Sultan Muhammad II of Kelantan in 1844 as
Kelantan's capital. Pantai Sabak, about 10 km from Kota Bharu, was the
initial landing point of the Japanese invasion forces on 8 December
1941 in their Malayan campaign when they successfully engaged the
British in jungle warfare  and ultimately captured Singapore. On 1
October 2005, Kota Bharu was declared Kota Bharu, The Islamic City.
This title is given to the city which observes Islamic principles in
every aspect of daily life. A majority of the people of Kota Bharu are
Muslims.  
Kubang Kerian is a town and also a parliamentary constituency of Kota
1Bharu district. The Universiti Sains Malaysia (USM) branch campus is
located about 10-15 minutes drive from Kota Bharu. This campus is also
referred to as the USM Health Campus established in 1983. The campus
houses 3 schools namely the School of Medical Sciences, the School of
Dentistry and the School of Health Sciences. The 731 bed teaching
hospital is located on campus. 113 beds were allocated for the
obstetrics and gynecology services.
Universiti Sains Malaysia (USM) had been granted the Apex (Accelerated
Programme for Excellence) status in transforming it into the first
world-class university of the country recently in April 2008. It was
the first of its kind in the country.  USM's transformation plan,
entitled Transforming Higher Education for a Sustainable Tomorrow
focused, among other things, on diagnostics, medical biotechnology,
waste management, pharmaceuticals, nano technology, carbon nanotube,
membrane technology and vaccinology become the fundamentals of the Apex
programme. The Apex status of the Universiti Sains Malaysia strives for
excellence and continuing research in medical field to provide better
healthcare and services.
There were 12 health centers in Kota Bharu district. The latest Klinik
Kesihatan in Kok Lanas was opened in 2007. The health centers were
Klinik Kesihatan (KK) Bandar, KK Kubang Kerian, KK Wakaf Che Yeh, KK
Penambang, KK Badang, KK Peringat, KK Ketereh, KK Perol, KK Lundang
Paku, KK Pengkalan Chepa, KK Kedai Lalat. At every health center, there
was maternal and child health services conducted at maternal and child
health clinics (MCHC). Basically MCHC provides services to mothers and
children. The services included antenatal and postnatal check-up,
immunization, and pediatrics clinic. Each MCHC covered a few community
clinics (Klinik Desa), sited at various parts of the sub-district and
provide similar services. There were 32 community clinics (Klinik Desa)
in Kota Bharu district. The tertiary referral hospitals for the state
of Kelantan were Hospital Raja Perempuan Zainab II (HRPZ II) and
Hospital Universiti Sains Malaysia (HUSM). 
Patients recruited for this study were mainly from the district of Kota
Bharu. However, HRPZII is a referral centre for obstetric patients from
Tumpat, Pasir Mas, Tanah Merah, Jeli and Machang. HUSM  is a referral
centre for obstetric patients mainly from Bachok, Pasir Puteh and
Besut, Terengganu. Occasionally, there are also referral cases from
other district of Kelantan such as Kuala Krai and Gua Musang.
Therefore, in term of locality of obstetric patients included in this
study, it covered a larger area than just Kota Bharu alone.
CHAPTER TWO: LITERATURE REVIEW
2.1 INTRODUCTION
Hypertension (high blood pressure) is common during pregnancy. Around
10% of women will have their blood pressure recorded as above normal at
some point before delivery. Preeclampsia (’toxaemia’) is defined as
hypertension accompanied by proteinuria (protein in the urine) (NHBPEP,
2000). It usually occurs during the second half of pregnancy and
complicates 2% to 8% of pregnancies (WHO, 1988). For women who have
hypertension alone, pregnancy outcome is similar to that for women with
normal blood pressure. Outcome deteriorates once proteinuria develops.
1 Many women with preeclampsia have no symptoms. Women with severe
preeclampsia, or very high blood pressure, may feel unwell with
symptoms such as headache, upper abdominal pain or visual disturbances.
Preeclampsia can lead to problems in the liver, kidneys, brain, and to
abnormalities of the clotting system. Rare but serious complications
include eclampsia (seizures in a woman with preeclampsia), stroke,
HELLP syndrome (haemolysis, elevated liver enzymes and low platelets)
and disseminated intravascular coagulation. These complications are
associated with an increased risk of maternal death. As preeclampsia
can affect the placenta, risks for the baby are also increased. The
most common problems are those related to poor intrauterine growth and
premature birth. Although the outcome following preeclampsia or
eclampsia is good for most women, these conditions remain major causes
of maternal mortality. 
Over half a million women die each year from pregnancy-related causes,
and 99% of these deaths occur in the developing world (WHO, 2005). In
poor countries, maternal mortality is still 100 to 200 times higher
than in Europe and North America. Women in industrialized countries
have an average lifetime risk (calculated as the average number of
pregnancies multiplied by the risk associated with each pregnancy) of
dying from pregnancy-related causes of between 1 in 4000 and 1 in
10,000, whereas women in low-income countries have a risk that is
between 1 in 15 and 1 in 50. There is no other public health statistic
for which the disparity between rich and poor countries is so wide. An
estimated 10% to 15% of maternal deaths in developing countries are
associated with preeclampsia or eclampsia (Duley, 1992; Khan et al,
2006), as are 13% to 15% of the direct obstetric deaths in the UK
(Lewis, 2007) and USA (ACOG, 1996).
 Perinatal mortality is also increased following preeclampsia (Ananth
et al, 1995; Roberts et al, 2005). There is less information about
morbidity for either mother or baby, but it is likely that this too is
high. For example, preeclampsia accounts for an estimated one fifth of
antenatal admissions (Rosenberg & Twaddle, 1990) and two thirds of
referrals to day care assessment units (Anthony, 1992) in the UK, and a
quarter of obstetric admissions to intensive care units in France
(Bouvier et al, 1996). For many women, developing preeclampsia can be a
difficult and unexpected experience especially if they become ill, give
birth too early or if their baby dies (Duley et al, 2006).
 There is also growing evidence that women who have had gestational
hypertension or preeclampsia are at increased risk later in life of
hypertension, stroke, and ischaemic heart disease (Bellamy et al, 2007;
Wilson et al, 2003), although it remains unclear whether this reflects
a common pathway or whether having preeclampsia increases this risk.
For the babies, preeclampsia is an antecedent for up to 12% of those
born small-for-gestational age (Kramer et al, 2000) and 19% of those
born preterm (Hewitt & Newnham, 1988). Such children are at an
increased risk of developmental delay and chronic ill health in
childhood. The underlying cause of preeclampsia remains unclear, and
the only definitive treatment is to end the pregnancy by delivering the
baby. The aim of interventions for women with preeclampsia is therefore
to treat the symptoms and prevent complications, and to optimize the
timing of delivery for the baby.
2.2 DEFINITION 
Preeclampsia is part of a spectrum of conditions known as the
hypertensive disorders of pregnancy. These disorders have a continuum
with normal pregnancy. During normal pregnancy there is enormous
maternal physiological adaptation to accommodate the growing fetus and
1placenta. For example, cardiac output increases by about 40% in the
first trimester. In contrast, blood pressure remains relatively
unchanged in the first trimester, falling by about 5 to 10 mmHg in the
second trimester, and rising back to pre-pregnancy levels by term.
Cardiac output is influenced by peripheral resistance and blood
pressure. As normal pregnancy is associated with increased cardiac
output and normal or slightly lowered blood pressure, peripheral
resistance falls (De Swiet, 2002). Changes in kidney function also
occur in normal pregnancy, with increased protein excretion especially
in the third trimester. In normal pregnancy, up to 300 mg protein in 24
hours output of urine is accepted as normal. 
Classification and definition of the hypertensive disorders of
pregnancy have, in the past, been controversial. More recently, there
has been a shift towards agreeing on and accepting standard
definitions, and ensuring they are relevant for clinical practice
(Brown et al, 2001). What follows is based on current consensus.
2.2.1 Definition of hypertension
Hypertension in pregnancy is usually defined as systolic blood pressure
of at least 140 mmHg, diastolic blood pressure of at least 90 mmHg, or
both. Any rise in blood pressure should be confirmed by a second
measurement, ideally at least four hours later. Because of
cardiovascular changes, automated blood pressure monitors
systematically underestimate blood pressure in pregnancy and
preeclampsia. If used, they should be calibrated regularly against a
mercury sphygmomanometer (Shennan & Waugh, 2003). The debate over which
auscultatory sound to use for assessment of diastolic blood pressure,
muffling (Korotkoff phase IV) or disappearance (Korotkoff phase V), has
been resolved, and Korotkoff V is now recommended as more reliable
(Brown et al, 2001).
2.2.2 Definition of proteinuria
Proteinuria during pregnancy is defined as 300 mg protein, or more, in
24 hours (Brown et al, 2001). In a single midstream urine sample, this
usually correlates with 30 mg/dL, 1+ or more on a dipstick, or a spot
urine protein/creatinine ratio of at least 30mg/mmol.
2.3 CLASSIFICATION
2.3.1  Gestational hypertension or pregnancy-induced hypertension
This is hypertension detected for the first time during the second half
of pregnancy (after 20 weeks’ gestation) in the absence of proteinuria.
It resolves within three months of birth.
2.3.2 Preeclampsia/eclampsia
Preclampsia is defined as hypertension and proteinuria detected for the
first time in the second half of pregnancy (after 20 weeks’ gestation).
Eclampsia is the occurrence of seizures in a woman with preeclampsia.
There is no widely accepted definition of severe preeclampsia.
Nevertheless, the following are widely regarded as features of severe
disease: severe hypertension (blood pressure at least 160 mmHg
systolic, or 110 mmHg diastolic), severe proteinuria (usually at least
3 g (range 2 g to 5 g) protein in 24 hours, or 3+ on dipstick), reduced
urinary volume (less than 500ml in 24 hours), neurological disturbances
such as headache, visual disturbances, and exaggerated tendon reflexes,
upper abdominal pain, pulmonary oedema (fluid in the lungs), impaired
liver function tests, high serum creatinine, low platelets,
intrauterine growth restriction or reduced liquor volume (Brown et al,
2000; NHBPEP, 2000).
12.3.3 Chronic hypertension
This is hypertension known to be present before pregnancy, or detected
before 20 weeks’ gestation. It is essential hypertension if there is no
underlying cause and secondary hypertension if there is an underlying
cause such as renal, cardiac, or endocrine disease. ‘Chronic’
hypertension may present for the first time as gestational
hypertension. Hence, gestational hypertension that does not resolve
after birth should be reclassified as chronic hypertension.
2.3.4 Preeclampsia superimposed on chronic hypertension
Women with chronic hypertension may then develop preeclampsia. This is
diagnosed where there is new onset of proteinuria, or sudden worsening
of either hypertension or proteinuria, or development of other signs
and symptoms of preeclampsia after 20 weeks’ gestation.
2.4 AETIOLOGY OF PREECLAMPSIA
Despite a growing understanding of the pathophysiology of preeclampsia,
the underlying cause of this syndrome remains unclear. Factors that
appear to have a role include maternal age, parity, obesity, maternal
immune response, genetic predisposition, and maternal vascular disease
(such as diabetes, chronic hypertension and autoimmune disease)
(Duckitt & Harrington, 2005). Diet and nutrition may also have a role.
Whether an individual woman will develop this syndrome probably depends
on which of these factors she has, and how they interact. 
Preeclampsia is thought to occur as a result of inadequate blood supply
to the placenta, related either to abnormal implantation, or to
increased demand from the placenta (for example, in a multiple
pregnancy). So, although preeclampsia is usually diagnosed in the
second half of pregnancy, the antecedents are present much earlier.
Current thinking is that inadequate blood supply to the placenta leads
to the release of unknown factors or materials into the maternal
circulation which activate or injure the endothelial cells, resulting
in endothelial dysfunction (abnormal functioning of cells lining blood
vessels) (Roberts & Lain, 2002). Endothelial dysfunction results in
widespread vasoconstriction and activation of platelets and the
coagulation system. Injured endothelial cells allow leakage of fluid
out of the blood vessels and into surrounding tissues, causing oedema
and a reduction in the circulating blood volume. There is then
inadequate blood flow to many of the woman’s organs, especially the
kidneys, liver, and brain. It is the vasoconstriction, micro clots, and
reduced circulating blood volume that result in the clinical
manifestations of preeclampsia.
Any satisfactory theory concerning the etiology and pathophysiology of
preeclampsia must account for the observation that hypertensive
disorders due to pregnancy are very much more likely to develop in
women who:
Are exposed to chorionic villi for the first time.
Are exposed to a superabundance of chorionic villi, as with twins or
hydatidiform mole.
Have preexisting vascular disease.
Are genetically predisposed to hypertension developing during
pregnancy.
Although chorionic villi are essential, they need not be located within
the uterus. A fetus is not a requisite for preeclampsia. Regardless of
precipitating etiology, the cascade of events that leads to the
preeclampsia syndrome is characterized by a host of abnormalities that
result in vascular endothelial damage with vasospasm, transudation of
plasma, and ischemic and thrombotic sequelae. Writings describing
eclampsia have been traced as far back as 2200 B.C. (Lindheimer et al,
1999). It is thus not surprising that a number of mechanisms have been
1proposed to explain its cause. Many of the absurd, and especially the
dangerous, thankfully have been discarded. According to Sibai (2003),
currently plausible potential causes include the following:
Abnormal trophoblastic invasion of uterine vessels.
Immunological intolerance between maternal and fetoplacental tissues.
Maternal maladaptation to cardiovascular or inflammatory changes of
normal pregnancy.
Dietary deficiencies.
Genetic influences. 
2.4.1 Abnormal Trophoblastic Invasion
In normal implantation, the uterine spiral arteries undergo extensive
remodeling as they are invaded by endovascular trophoblasts. In
preeclampsia, however, there is incomplete trophoblastic invasion. In
this case, decidual vessels, but not myometrial vessels, become lined
with endovascular trophoblasts. In 1994, Meekins et al described a
continuum in the number of spiral arteries with endovascular
trophoblasts in placentas of normal women and in those with
preeclampsia. Madazli et al (2000) showed that the magnitude of
defective trophoblastic invasion of the spiral arteries correlated with
the severity of the hypertensive disorder. 
Using electron microscopy, De Wolf and co-workers (1980) examined
arteries taken from the uteroplacental implantation site. They observed
that early preeclamptic changes included endothelial damage, insudation
of plasma constituents into vessel walls, proliferation of myointimal
cells, and medial necrosis. They found that lipid accumulates first in
myointimal cells and then in macrophages. Typically, the vessels
affected by atherosis develop aneurysmal dilatation and are frequently
found in association with spiral arterioles that have failed to undergo
normal adaptation (Khong, 1991). Obstruction of the spiral arteriolar
lumen by atherosis may impair placental blood flow. It is thought that
these changes cause placental perfusion to be pathologically
diminished, which eventually leads to the preeclampsia syndrome (Lain
and Roberts, 2002; Redman and Sargent, 2003).
2.4.2 Immunological Factors
There is circumstantial evidence to support the theory that
preeclampsia is immune mediated. Certainly the microscopic changes at
the maternal–placental interface are suggestive of acute graft
rejection (Labarrere, 1988). There are also inferential data. For
example, the risk of preeclampsia is appreciably enhanced in
circumstances where formation of blocking antibodies to placental
antigenic sites might be impaired. This may arise in situations in
which effective immunization by a previous pregnancy is lacking, as in
first pregnancies; or in which the number of antigenic sites provided
by the placenta is unusually great compared with the amount of
antibody, as with multiple fetuses (Beer, 1978). "Immunization" from a
prior abortion does not seem to occur. Strickland and associates (1986)
analyzed outcomes of over 29,000 pregnancies at Parkland Hospital and
reported that hypertensive disorders were decreased only slightly (22
versus 25 percent) in women who previously had miscarried (thus who
were previously "immunized") and were now having their first advanced
pregnancy. The immunization concept was supported by their observations
that preeclampsia developed less often in multiparas who had a prior
term pregnancy. Other studies have shown that multiparous women
impregnated by a new consort have an increased risk of preeclampsia
(Mostello et al, 2002; Trupin et al, 1996).
Dekker and Sibai (1998) have reviewed the possible role of immune
maladaptation in the pathophysiology of preeclampsia. Beginning in the
early second trimester, women destined to develop preeclampsia have a
significantly lower proportion of helper T cells (Th1) compared with
that of women who remain normotensive (Bardeguez et al, 1991). This
1Th1/Th2 imbalance, with Th2 dominance, may be mediated by adenosine,
which is found in higher serum levels in preeclamptic compared with
normotensive women (Yoneyama et al, 2002). These helper T lymphocytes
secrete specific cytokines that promote implantation, and their
dysfunction may favor preeclampsia (Hayashi et al, 2004; Whitecar et
al, 2001).
In women with anticardiolipin antibodies, placental abnormalities and
preeclampsia develop more commonly. According to Katano and colleagues
(1996), antibodies associated with glycoprotein I appear most relevant.
Immune complexes and anti-endothelial cell antibodies may also be
involved (Taylor and Roberts, 1999).
2.4.3 The Vasculopathy and the Inflammatory Changes
In many ways, inflammatory changes are a continuation of the placental
causes discussed above. In response to placental factors released by
ischemic changes, or any other inciting cause, a cascade of events is
set in motion (Redman and Sargent, 2003). The decidua also contains an
abundance of cells that, when activated, can release noxious agents
(Staff et al, 1999). These then serve as mediators to provoke
endothelial cell injury.
Redman et al (1999) have proposed that the endothelial cell dysfunction
associated with preeclampsia can result from a "generalized
perturbation of the normal, generalized maternal intravascular
inflammatory adaptation to pregnancy". In this hypothesis, preeclampsia
is considered a disease due to an extreme state of activated leukocytes
in the maternal circulation (Gervasi et al, 2001). Briefly, cytokines
such as tumor necrosis factor (TNF) and the interleukins may contribute
to the oxidative stress associated with preeclampsia. Oxidative stress
is characterized by reactive oxygen species and free radicals that lead
to formation of self-propagating lipid peroxides (Manten et al, 2005).
These in turn generate highly toxic radicals that injure endothelial
cells, modify their nitric oxide production, and interfere with
prostaglandin balance.
Not all investigators have confirmed these findings. Diedrich et al
(2001) did not detect any lipid hydroperoxides in 38 preeclamptic women,
10 of whom had HELLP syndrome (hemolysis, elevated liver enzymes, and
low platelets). They did, however, find other evidence of oxidative
stress. Other consequences of oxidative stress include production of the
lipid-laden macrophage foam cells seen in atherosis; activation of
microvascular coagulation, seen in thrombocytopenia; and increased
capillary permeability, seen in edema and proteinuria.
These observations on the effects of oxidative stress in preeclampsia
have given rise to increased interest in the potential benefit of
antioxidants to prevent preeclampsia (Chappell et al, 1999; Zhang et al,
2002). Antioxidants are a diverse family of compounds that function to
prevent overproduction of and damage caused by noxious free radicals.
Examples of antioxidants include vitamin E (tocopherol), vitamin C
(ascorbic acid), and beta-carotene. 
2.4.4 Nutritional Factors
A number of dietary deficiencies or excesses over the centuries have
been blamed as the cause of eclampsia. Dietary taboos that have included
meat, protein, purines, fat, dairy products, salt, and other elements
have been advocated at times. Observations and theories led to studies
of dietary deprivation of various sorts that many times were models of
absurdity. In more recent times, sanity and a scientific approach have
prevailed. For example, blood pressure in non pregnant individuals is
affected by a number of dietary influences, including minerals and
vitamins. Some studies have shown a relationship between dietary
deficiencies and the incidence of preeclampsia. This was followed by
studies of supplementation with various elements such as zinc, calcium,
and magnesium to prevent preeclampsia. Other studies, such as the one by
John and co-workers (2002), showed that in the general population a diet
1high in fruits and vegetables that have antioxidant activity is
associated with decreased blood pressure. This is related to the
case-control study by Zhang et al (2002) cited above, in which the
incidence of preeclampsia was doubled in women whose daily intake of
ascorbic acid was less than 85 mg.
Obesity is a potent risk factor for preeclampsia. Evidence has accrued
that obesity in non pregnant individuals’ causes endothelial activation
and a systemic inflammatory response associated with atherosclerosis
(Ross, 1999). In the study of pregnant women by Wolf and colleagues
(2001), C-reactive protein, an inflammatory marker, was shown to be
increased in obesity, which in turn was associated with preeclampsia.
2.4.5 Genetic Factors
The predisposition to hereditary hypertension undoubtedly is linked to
preeclampsia (Ness et al, 2003), and the tendency for
preeclampsia/eclampsia is inherited. Chesley and Cooper (1986) studied
sisters, daughters, granddaughters, and daughters-in-law of eclamptic
women and concluded that preeclampsia/eclampsia is highly heritable. The
single-gene model, with a frequency of 0.25, best explained their
observations. Other investigators cite possibilities of polygenic
inheritance (Trogstad et al, 2004). A Swedish study by Nilsson et al
(2004) that included almost 1.2 million births reported a genetic
component for gestational hypertension as well as preeclampsia. They
reported 60-percent concordance in monozygotic female twin pairs, which
was much higher than that found by Treloar and co-workers (2001).
2.5 PATHOGENESIS OF PREECLAMPSIA
2.5.1 Vasospasm
The initial concept of vasospasm was based on direct observations of
small blood vessels in the nail beds, ocular fundi, and bulbar
conjunctivae. It was also surmised from histological changes seen in
various affected organs (Landesman et al, 1954). Vascular constriction
causes resistance and subsequent hypertension. At the same time,
endothelial cell damage causes interstitial leakage through which blood
constituents, including platelets and fibrinogen, are deposited
subendothelially. Wang et al (2002) have also demonstrated disruption of
endothelial junctional proteins. Suzuki et al (2003) demonstrated
ultrastructural changes in the subendothelial region of resistance
arteries in preeclamptic women. With diminished blood flow because of
maldistribution, ischemia of the surrounding tissues would lead to
necrosis, hemorrhage, and other end-organ disturbances characteristic of
the syndrome. Ironically, vasospasm may be worse in women with
preeclampsia than in those with the HELLP syndrome (Fischer et al,
2000).
2.5.2 Endothelial Cell Activation
Over the past two decades, endothelial cell activation has become the
centerpiece in the contemporary understanding of the pathogenesis of
preeclampsia. In this scheme, unknown factors, likely from the placenta,
are secreted into the maternal circulation and provoke activation and
dysfunction of the vascular endothelium. The clinical syndrome of
preeclampsia is thought to result from these widespread endothelial cell
changes (Hayman et al, 2000).
Intact endothelium has anticoagulant properties, and it also blunts the
response of vascular smooth muscle to agonists by releasing nitric
oxide. Damaged or activated endothelial cells secrete substances that
promote coagulation and increase the sensitivity to vasopressors.
Further evidence of endothelial activation includes the characteristic
changes in glomerular capillary endothelial morphology, increased
capillary permeability, and elevated blood concentrations of substances
associated with such activation. These latter substances are
transferrable, and serum from women with preeclampsia stimulates
cultured endothelial cells to produce greater amounts of prostacyclin
than serum from normal pregnant women.
12.5.3 Increased Pressor Responses
Normally, pregnant women develop refractoriness to infused vasopressors
(Abdul-Karim & Assali, 1961). Women with early preeclampsia, however,
have increased vascular reactivity to infused norepinephrine and
angiotensin II (Raab et al, 1956). Moreover, increased sensitivity to
angiotensin II clearly precedes the onset of gestational hypertension.
Normotensive nulliparas remained refractory to infused angiotensin II,
but those who subsequently became hypertensive lost this refractoriness
several weeks before the onset of hypertension. Women with underlying
chronic hypertension have almost identical responses (Gant et al, 1977).
2.5.4 Prostaglandins
A number of prostanoids are central to the pathophysiology of the
preeclampsia syndrome. Specifically, the blunted pressor response seen
in normal pregnancy is at least partially due to decreased vascular
responsiveness mediated by vascular endothelial prostaglandin
synthesis. For example, when compared with normal pregnancy,
endothelial prostacyclin (PGI2) production is decreased in
preeclampsia. This action appears to be mediated by phospholipase A2
(Taylor & Roberts, 1999). At the same time, thromboxane A2 secretion by
platelets is increased, and the prostacyclin: thromboxane A2 ratio
decreases. The net result favors increased sensitivity to infused
angiotensin II, and ultimately, vasoconstriction. Chavarria et al
(2003a) have provided evidence that these changes are apparent as early
as 22 weeks in women who later develop preeclampsia.
2.5.5 Nitric Oxide
This potent vasodilator is synthesized from L-arginine by endothelial
cells. Withdrawal of nitric oxide results in a clinical picture similar
to preeclampsia in a pregnant animal model (Weiner et al, 1989). In
other animal studies, inhibition of nitric oxide synthesis increases
mean arterial pressure, decreases heart rate, and reverses the
pregnancy-induced refractoriness to vasopressors. In humans, nitric
oxide likely is the compound that maintains the normal low-pressure
vasodilated state characteristic of fetoplacental perfusion (Weiner et
al, 1992). It also is produced by fetal endothelium and is increased in
response to preeclampsia, diabetes, and infection (Parra et al, 2001).
Preeclampsia is associated with decreased endothelial nitric oxide
synthase expression, which increases cell permeability (Wang et al,
2004). There is not decreased nitric oxide release or production prior
to the onset of hypertension (Anumba et al, 1999). Its production is
increased in severe preeclampsia possibly as a compensatory mechanism
for the increased synthesis and release of vasoconstrictors and
platelet-aggregating agents (Benedetto et al, 2000). Thus, increased
serum concentrations of nitric oxide in women with preeclampsia are
likely the result of hypertension, not the cause (Morris et al, 1996).
2.5.6 Endothelins
These 21–amino acid peptides are potent vasoconstrictors, and
endothelin-1 (ET-1) is the primary isoform produced by human
endothelium (Mastrogiannis et al, 1991). Plasma ET-1 is increased in
normotensive pregnant women, but women with preeclampsia have even
higher levels (Ajne et al, 2003). According to Taylor & Roberts (1999),
the placenta is not the source of increased ET-1 and it likely arises
from systemic endothelial activation. Interestingly, treatment of
preeclamptic women with magnesium sulfate lowers ET-1 concentrations
(Sagsoz & Kucukozkan, 2003).
2.5.7 Angiogenic Factors
Several glycosylated glycoproteins are selectively mitogenic for
endothelial cells and are thought to be important in mediating the
preeclampsia syndrome. Two of these are vascularendothelial growth
factor (VEGF) and placental growth factor (PlGF). Their secretion
increases across normal pregnancy, and they promote angiogenesis and
1induce nitric oxide and vasodilatory prostaglandins, discussed above.
Placental VEGF is important in vasculogenesis and control of
microvascular permeability. Paradoxically, VEGF is increased in serum
from women with preeclampsia but its bioavailability is decreased
(Baker et al, 1995; Simmons et al, 2000). 
2.6 PATHOPHYSIOLOGY 
By strict definition, preeclampsia–eclampsia fits the definition of a
syndrome: A group of symptoms or pathological signs which consistently
occur together, especially with an (originally) unknown cause (Oxford
English Dictionary, 1993). Although the cause of preeclampsia remains
unknown, evidence for it begins to manifest early in pregnancy with
covert pathophysiological changes that gain momentum across gestation.
Unless delivery supervenes, these changes ultimately result in
multiorgan involvement with a clinical spectrum ranging from barely
noticeable to one of cataclysmic pathophysiological deterioration that
can be life threatening for both mother and fetus. These adverse
maternal and fetal effects develop simultaneously. As discussed, these
presumably are a consequence of vasospasm, endothelial dysfunction, and
ischemia. The myriad of maternal consequences of the preeclampsia
syndrome are described in terms of organ systems, but they frequently
overlap. It is enigmatic that there are such wide variations of
involvement of these systems in individual pregnancies.
2.6.1 Cardiovascular System
Severe disturbances of normal cardiovascular function are common with
preeclampsia or eclampsia. These are related to increased cardiac
afterload caused by hypertension, cardiac preload, which is
substantively affected by pathologically diminished hypervolemia of
pregnancy or is iatrogenically increased by intravenous crystalloid or
oncotic solutions, and endothelial activation with extravasation into
the extracellular space, especially the lung. In addition, left
ventricular mass is increased relative to normal pregnancy (Borghi et
al, 2000).
The cardiovascular aberrations of hypertensive disorders of pregnancy
vary depending on a number of factors. Some of these include severity
of hypertension, presence of underlying chronic disease, whether
preeclampsia is present, and at what point in the clinical course they
are studied. For example, some of these changes precede the onset of
hypertension. Bosio et al (1999) used noninvasive Doppler hemodynamic
monitoring in a longitudinal study of 400 nulliparous women commencing
early in pregnancy. Gestational hypertension developed in 24 women, and
20 others had preeclampsia. Compared with normotensive women, the women
who developed preeclampsia had significantly elevated cardiac outputs
before hypertension developed. This substantiates earlier observations
of Easterling et al (1990), except that the latter group reported
increased peripheral resistance during this preclinical phase. With
clinical onset of preeclampsia, there was a marked reduction in cardiac
output and increased peripheral resistance. By contrast, the women with
gestational hypertension maintained their significantly elevated
cardiac outputs with development of hypertension.
It has been known for over 75 years that hemoconcentration is a
hallmark of eclampsia. Zeeman and colleagues (2004b) expanded the
previous observations of Pritchard and co-workers (1984) that in
eclamptic women the normally expected hypervolemia was severely
curtailed or even absent. Women of average size should have a blood
volume of nearly 5000 mL during the last several weeks of a normal
pregnancy, compared with about 3500 mL when they are not pregnant. With
eclampsia, however, much or all of the anticipated excess 1500 mL of
blood normally present is absent. Such hemoconcentration is likely the
consequence of generalized vasoconstriction and endothelial dysfunction
with vascular permeability. In women with preeclampsia, and depending
1on severity, hemoconcentration is usually not as marked, whereas women
with gestational hypertension usually have a normal blood volume
(Silver et al, 1998).
For women with severe hemoconcentration, it was once taught that an
acute fall in hematocrit suggested resolution of preeclampsia. However,
this usually is the consequence of blood loss, even of normal amounts,
at delivery. It may also be partially the result of intense erythrocyte
destruction as subsequently described.
In the absence of hemorrhage, the intravascular compartment in
eclamptic women is usually not under filled. Vasospasm and endothelial
leakage of plasma has contracted the space to be filled. These changes
persist until a variable amount of time after delivery when the
vascular endothelium repairs. Vasodilation then occurs, and as the
blood volume increases, the hematocrit usually falls. Thus, women with
eclampsia:
Are unduly sensitive to vigorous fluid therapy administered in an
attempt to expand the contracted blood volume to normal pregnancy
levels.
Are quite sensitive to even normal blood losses at delivery.
2.6.2 Blood and Coagulation
Hematological abnormalities develop in some women with preeclampsia.
Among these are thrombocytopenia, which at times may become as severe
as to be life threatening. In addition, the levels of some plasma
clotting factors may be decreased, and erythrocytes may display bizarre
shapes and undergo rapid hemolysis.
Because thrombocytopenia can be induced acutely by
preeclampsia/eclampsia, the platelet count is routinely measured in
hypertensive pregnant women. The frequency and intensity of maternal
thrombocytopenia varies and likely is dependent on the intensity of the
disease process, duration of preeclampsia, and the frequency with which
platelet counts are performed. Overt thrombocytopenia, defined by a
platelet count less than 100,000/µL, indicates severe disease. In most
cases, delivery is indicated because the platelet count continues to
decrease. After delivery, the platelet count increases progressively to
reach a normal level within 3 to 5 days. Thrombocytopenia results from
platelet activation, aggregation, and consumption that are accompanied
by increased mean platelet volume and decreased life span (Harlow et
al, 2002). 
The clinical significance of thrombocytopenia, in addition to any
impairment in coagulation, is that it reflects the severity of the
pathological process. In general, the lower the platelets count, the
higher the maternal and fetal morbidity and mortality (Leduc et al,
1992). In 1954, Pritchard and colleagues called attention to
thrombocytopenia accompanied by elevated serum liver transaminase
levels in women with eclampsia. Weinstein (1982) later referred to this
combination of events as the HELLP syndrome—hemolysis (H), elevated
liver enzymes (EL), and low platelets (LP)—and this moniker now is used
worldwide.
Subtle changes consistent with intravascular coagulation, and less
often erythrocyte destruction, commonly are found with preeclampsia and
especially eclampsia (Baker & Cunningham, 1999). Since the early
description by Pritchard and co-workers (1954) of coagulation
abnormalities in women with eclampsia, there is little evidence that
these abnormalities are clinically significant (Pritchard et al, 1984).
Except for thrombocytopenia, discussed above, laboratory aberrations
generally are mild. Unless there is associated placental abruption,
plasma fibrinogen levels do not differ remarkably from levels found in
normal pregnancy, and fibrin degradation products are elevated only
occasionally. Barron and colleagues (1999) found routine laboratory
assessment of coagulation, including prothrombin time, activated
1partial thromboplastin time, and plasma fibrinogen level, to be
unnecessary in the management of pregnancy-associated hypertensive
disorders. The thrombin time is somewhat prolonged in a third of the
cases of eclampsia even when elevated levels of fibrin degradation
products are not identified. The reason for this elevation is not
known, but it has been attributed to hepatic derangements discussed
subsequently (Leduc et al, 1992).
2.6.3 Volume Homeostasis
Plasma levels of renin, angiotensin II, and aldosterone are increased
during normal pregnancy. With preeclampsia, these values decrease
toward the normal nonpregnant range (Weir et al, 1973). With sodium
retention, hypertension, or both, renin secretion by the
juxtaglomerular apparatus decreases. Renin catalyzes the conversion of
angiotensinogen to angiotensin I, which is then transformed into
angiotensin II by angiotensin-converting enzyme (ACE). Thus, with
preeclampsia, angiotensin II levels decline, resulting in a decrease in
aldosterone secretion. Despite this, women with preeclampsia avidly
retain infused sodium (Brown et al, 1988b).
Vasopressin levels are normal in women with preeclampsia despite
decreased plasma osmolality (Lindheimer et al, 1999). During normal
pregnancy, serum concentrations of atrial natriuretic peptide are
maintained in the nonpregnant range despite the increased plasma
volume. The peptide is released on atrial wall stretching from blood
volume expansion. It is vasoactive and promotes sodium and water
excretion, probably by inhibiting aldosterone, renin activity,
angiotensin II, and vasopressin. Secretion of atrial natriuretic
peptide is increased in women with preeclampsia (Lindheimer et al,
1999). Increases in atrial natriuretic peptide following volume
expansion result in comparable increases in cardiac output and
decreases in peripheral vascular resistance in both normotensive and
preeclamptic women (Nisell et al, 1992). This observation may in part
explain observations of a fall in peripheral vascular resistance
following volume expansion in preeclamptic women.
The volume of extracellular fluid, manifest as edema, in women with
severe preeclampsia is usually expanded beyond that of normal pregnant
women. The mechanism responsible for pathological fluid retention is
thought to be endothelial injury. In addition to generalized edema and
proteinuria, these women have reduced plasma oncotic pressure, which
creates a filtration imbalance, further displacing intravascular fluid
into the surrounding interstitium.
Electrolyte concentrations do not differ appreciably in women with
preeclampsia compared with normal pregnant women unless there has been
vigorous diuretic therapy, sodium restriction, or administration of
free water with sufficient oxytocin to produce antidiuresis.
Following an eclamptic convulsion, the serum pH and bicarbonate
concentration are lowered due to lactic acidosis and compensatory
respiratory loss of carbon dioxide. The intensity of acidosis relates
to the amount of lactic acid produced and its metabolic rate, as well
as the rate at which carbon dioxide is exhaled.
2.6.4 Uteroplacental Perfusion
Compromised uteroplacental perfusion from vasospasm is almost certainly
a major culprit in the genesis of increased perinatal morbidity and
mortality associated with preeclampsia. Brosens and associates (1972)
reported that the mean diameter of myometrial spiral arterioles of 50
normal pregnant women was 500 µm. The same measurement in 36 women with
preeclampsia was 200 µm. Attempts to assess human maternal and
placental blood flow have been hampered by several obstacles, including
inaccessibility of the placenta, the complexity of its venous effluent,
and the unsuitability of certain investigative techniques for humans.
Measurement of blood flow velocity through uterine arteries has been
used to estimate resistance to uteroplacental blood flow. Vascular
1resistance is estimated by comparing arterial systolic and diastolic
velocity waveforms. Earlier studies were done to assess this by
measuring these ratios from uterine and umbilical arteries in
preeclamptic pregnancies. The findings indicated that in some cases,
but certainly not all, there was increased resistance (Ducey et al,
1987). Matijevic & Johnston (1999) used color pulsed Doppler
velocimetry to measure resistance in uterine spiral arteries. Impedance
was higher in peripheral than in central vessels. This has been termed
a "ring-like" distribution. Mean resistance was higher in all women
with preeclampsia compared with normotensive controls.
2.7 MANAGEMENT
2.7.1 Prophylactic therapies
The key to modern management of preeclampsia is close surveillance and
timely delivery prior to serious consequences. In an ideal world
preventing the manifestation of the disease would be far more
preferable. Aspirin, calcium, and antioxidants have all been
investigated, with some evidence of success (Ruano et al, 2005). 
Low-dose aspirin reverses the imbalance between the vasoconstrictor
thromboxane A2 and the vasodilator prostacyclin, which is known to
occur in preeclampsia. There are 42 randomized controlled trials
published in the Cochrane collaboration demonstrating a 15% relative
risk reduction in preeclampsia when either aspirin or other
antiplatelet agents are given. There is a similar reduction (14%) in
the risk of death to the baby as well as an 8% reduction in the risk of
preterm delivery (Duley et al, 2001). It is generally accepted that
aspirin should be considered in high-risk women. Benefit is seen when
the prevalence of preeclampsia is only 7%, and one baby death can be
prevented for every 250 treated (Duley et al, 2003). The evidence
demonstrates it is safe. There are ongoing investigations as to the
appropriate dose and timing as well as the population to be targeted.
1There are 10 trials in nearly 7000 women demonstrating the beneficial
role of calcium as preeclamptic prophylaxis and overall there is a
significant reduction in the incidence of preeclampsia (Atallah et al,
2002). However, this is largely related to the success in trials in
women with inadequate calcium intake, and the benefit to the baby is
not as clear as aspirin. The investigations into the use of fish oils
containing N3 fatty acid known to inhibit platelet thromboxane A2 have
not shown a significant reduction in preeclampsia. As oxidative stress
is known to be fundamental to the disease process one trial
demonstrated that vitamin C and E supplementation in the second
trimester of pregnancy may be beneficial, demonstrating more than a 50%
reduction when high-risk women were treated (Chappel et al, 1999). This
involved 1000 mg vitamin C and 400 IU vitamin E, which are known to act
synergistically; however, further studies which are currently ongoing
need to confirm this.
2.7.2 Assessment of the mother
The threshold of hypertension and proteinuria are relatively low to
diagnose preeclampsia, so the first key aspect of management involves
confirming the diagnosis to ensure that iatrogenic morbidity does not
ensue. Hypertension that occurs in early pregnancy, that is, before 28
weeks’ gestation results in preeclampsia developing in approximately
50% of women. In contrast women who present at term with hypertension
are unlikely to develop preeclampsia (approximately a 10% risk). Care
in assessing both blood pressure and proteinuria can improve assessment
as false positive and negative tests are commonplace. 
The syndrome of preeclampsia is multisystemic, and other organ
involvement must be carefully considered, including the placenta. A
careful history should also include whether women have symptoms such as
visual disturbance, headaches and epigastric pain. Sometimes nausea or
even vomiting can be a presenting feature. However, at least 50% of
women even with severe disease will be asymptomatic (Douglas & Redman,
1994). When managing women particularly remote from term, involvement
of all organ systems must be carefully investigated. Platelets are
consumed due to the endothelial activation. A falling count,
particularly to less than 100 × 109/l may indicate a need to consider
delivery. Counts above 50 are likely to support haemostasis. An
increasing haematocrit or haemoglobin indicates hypovolaemia, which is
characteristic of severe disease. If labour is anticipated then
clotting abnormalities should be checked as preeclampsia can cause
disseminated intravascular coagulation. This is important if regional
anaesthesia is used, which is preferable to general anaesthesia.
 Renal tubular function can be assessed by measuring uric acid, which
is a marker of disease severity, although normal levels can occur in
severe disease. Acute fatty liver can result in spuriously high levels
of uric acid (along with high white cell count, and low glucose). Urea
and creatinine are associated with late renal involvement and generally
not useful as indicators of disease severity. Liver transaminases
should be measured to indicate hepatocellular damage. Normal ranges of
transaminases are approximately 20% lower than non-pregnant (Girling et
al, 1997). Subcapsular involvement of the liver can occur, resulting in
epigastric pain with normal transaminase measurements. HELLP
(Haemolysis, Elevated Liver Enzymes, and Low Platelets) syndrome occurs
when liver involvement is associated with haemolysis and low platelets.
This is a severe variant of preeclampsia. When protein excretion
exceeds 3 g in 24 h, the circulating albumin is likely to fall
(nephrotic syndrome) and this increases the risk of pulmonary oedema.
Lactate dehydrogenase levels will increase in the presence of
haemolysis.
Antenatal corticosteroids should be given to enhance fetal lung
maturity, and are not contraindicated in preeclampsia. Steroid therapy
1is also known to help recovery from HELLP syndrome and has been used in
the post-partum period. Antenatal corticosteroids may actually improve
biochemical markers in women with preeclampsia. The treatment of blood
pressure should be reserved principally for severe hypertension, that
is, blood pressures over 160/110 mmHg. However, this does require
urgent therapy. Treatment of moderate hypertension maybe detrimental to
fetal growth (Von Dadelszen et al, 2000), and moderate blood pressure
should not be aggressively treated. Once fetal lung maturity is likely
to be adequate, delivery should be considered, that is, after 32 weeks’
gestation. Multiorgan involvement or fetal compromise would be
indications for delivery. Close inpatient supervision is otherwise
required and can be considered prior to 32 weeks’ gestation or when the
benefit of conservative management is judged to outweigh delivery.
Conservative management will reduce neonatal morbidity, without
substantially increasing maternal problems. Recent evidence suggests
that under 30 week’s neonatal morbidity is high, and conservative
management is desirable (Shear et al, 2005). However, at least one
third of women still need to be delivered for fetal reasons less than
34 weeks. The inability to control hypertension, deteriorating liver or
renal function, progressive fall in platelet or albumin, or
neurological complications would be indications for maternal delivery
at any gestation.
2.7.3 Fetal assessment
Early onset preeclampsia is particularly involved with placental
insufficiency, and more than half of babies born before 34 weeks will
be growth restricted (Shear et al, 2005). This also explains why
abruption is more common, occurring in about1 in 20 of these early
onset cases. Fetal well-being should always be carefully considered in
all cases of preeclampsia, and includes a symphyseal fundal height
assessment, as well as a general enquiry as to fetal movements. At
early gestations an ultrasound scan must be performed to assess fetal
growth, and should include determination of the amniotic fluid index
and umbilical artery Doppler waveforms. A non-reactive CTG with
decelerations or a fetal condition that is deteriorating warrants
delivery, as it is unlikely to improve with time and may worsen with
antihypertensive therapy.
2.7.4 Intrapartum care of preeclampsia
Many units have now developed a severe preeclampsia protocol. Cases
which require protocol determined management are often defined as those
with severe hypertension (greater than 160/110 mmHg) or hypertension
with an additional complication such as headache, visual disturbance,
epigastric pain, clonus (more than three beats) or a platelet count
less than 100 x 109 or AST more than 50 IU units per litre.
The confidential enquiry into maternal deaths demonstrates that the two
main reasons why women die are cerebral haemorrhage or adult/acute
respiratory distress syndrome (CEMD UK, 2001). The two most important
factors that contribute to these deaths are therefore severe
hypertension and fluid intake. The control of blood pressure and fluid
balance is therefore critical. In contrast to pulmonary causes of
death, in recent years, deaths related to intracerebral haemorrhage
have not been reduced; suggesting control of blood pressure remains
suboptimal through poor monitoring and treatment.
2.7.5 Blood pressure control
Blood pressure should be measured frequently (at least every 15 min).
Automated sphygmomanometers can be used to facilitate this, or
alternatively intra-arterial readings can be assessed via a peripheral
arterial pressure transducer. As non-invasive measurements are obtained
principally by oscillometric blood pressure devices, which
underestimate blood pressure in preeclampsia (Natarajan et al, 1999).
Significant changes in blood pressure should be confirmed using mercury
1sphygmomanometry. Some devices are now accurate, and only those
specifically assessed for accuracy in preeclampsia should be purchased
in the future (Golara et al, 2002). On an individual patient basis the
accuracy of any device used should be established against an observer
using standard sphygmomanometry, preferably with a mercury
sphygmomanometer. Mean arterial
pressures (MAP) are generally used to guide management in protocols.
Antihypertensive therapy should be instigated when the MAP is =125
mmHg, or urgently if >140mmHg as above this cerebral autoregulation of
pressure is not reliable. Either hydrallazine or labetalol can be used
as a first line treatment, although labetalol is favoured (Magee et al,
2003). 
As these are important emergency measures in preventing stroke,
clinicians involved in the management of severe preeclampsia should be
familiar with treatment regimes. Some protocols advocate infusing a
colloid to protect the uteroplacental circulation if the baby is
undelivered. This should be done with caution, and careful
consideration to the impact of the overall fluid management, and
preferably under central venous pressure (CVP) surveillance.
2.7.6 Control of fluid balance
Strict monitoring of input and output is essential in the preeclamptic
patient. A combination of the reduced intravascular volume, leaking
capillaries and low albumin make women prone to pulmonary oedema. Renal
failure is a rare complication of preeclampsia but should be considered
when there has been inadequate transfusion or profound hypotension
following post-partum bleeding, as there is reduced intravascular
volume. Oliguria is relatively common, and strict monitoring should be
considered rather than aggressive blind fluid replacement.
Administration of intravenous fluid in the oliguric patient must be
done with caution. Most protocols will limit fluid intake to
approximately 1 ml/kg/h. CVP monitoring and Foley catheter insertion
should be used whenever possible. Repetitive fluid challenges should be
avoided in the absence of invasive monitoring. Should the CVP be high
(>8mmHg) with persistent oliguria then a dopamine infusion can be
considered (1 ì/kg/min.) Haemodialysis or haemofiltration maybe
necessary if the creatinine or potassium rises. Close communication
with a renal physician should be sought. Administration of diuretics
will only temporarily improve urine output, and confounds the reduced
circulating volume. Frusemide should therefore be reserved for treating
pulmonary oedema. Pulmonary artery catheterization should be considered
in difficult cases.
2.7.7 Anticonvulsant management
An eclamptic fit is usually self-limiting; however, anticonvulsive
therapy should be given to abort it when possible. Magnesium sulphate
can be used to control such a fit (up to 8 mg given by slow intravenous
infusion). Diazepam 10 mg can also be used but its anticonvulsant
properties are short-lived as compared to its sedative properties. In
those women who have prolonged fitting a brain scan is required to rule
out an intracerebral bleed. Following an eclamptic fit magnesium
sulphate is the prophylaxis of choice (Collaborative Eclampsia Trial,
1995). 
Magnesium sulphate has been demonstrated to reduce cerebral ischaemia
by acting as membrane stabilizer and vasodilator and is superior to
both diazepam and phenytoin in preventing further fits. It is also
associated with a significant reduction in the need for maternal
ventilation and intensive care admissions. Magnesium sulphate is given
in a 4 g intravenous loading dose in an infusion of 1 g/h. Some
protocols suggest 2 g/h but efficacy has been demonstrated at 1 g/h. It
is renally excreted so therefore in cases of oliguria or rising urea
care must be taken regarding toxicity and this is detected by absence
1of patellar reflexes. Respiratory arrest and muscle paralysis along
with cardiac arrest can occur and an antidote is 10 ml of 10% calcium
gluconate. 
Even with severe preeclampsia, eclamptic fits are rare and occur in
less than 2%. The Magpie trial evaluated giving magnesium sulphate
versus placebo in women with pre-eclampsia and there was a significant
reduction in fits in those women receiving treatment; magnesium
sulphate will roughly halve the incidence of eclampsia (Magpie Trial,
2002). The evidence also suggests that there are less maternal deaths
but trials have not been large enough to show that this is
significantly so. The threshold for giving magnesium sulphate to a
preeclamptic woman is uncertain but generally as the risk increases the
benefit favours therapy.
2.7.8 Anaesthetic management
Endotracheal intubation can cause severe hypertension and general
anaesthetic should be avoided (Allen et al, 1991). Regional blockade is
therefore the anaesthesia of choice; prior to insertion a coagulopathy
should be excluded. Platelet levels of more than 80 × 109 are likely to
ensure haemostasis and most obstetric anaesthetists would be happy to
perform this procedure under such circumstances. In women who have a
Caesarean section a low threshold for invasive CVP monitoring is
necessary. Careful management of fluid particularly following
post-partum haemorrhage is essential. Following delivery one in three
eclamptic fits will occur in the post-partum period most of these
within 48 h (Douglas & Redman, 1994). Although eclampsia has been
reported beyond this time it is not usually associated with serious
morbidity and generally anticonvulsant prophylaxis can be stopped
within a 48-h period. Blood pressure should be monitored carefully for
at least 4 days following delivery as the highest reading can occur at
this time (Atterbury et al, 1998). Quite frequently it is necessary to
give women antihypertensive therapy at home and follow-up is
recommended at 6 weeks. Methyldopa generally has unwanted side effects
and other common antihypertensive therapies can be used.
2.7.9 Post-natal management
At the post-natal follow-up both blood pressure and urine should be
checked for underlying renal and cardiovascular abnormalities. It is
now clear that women who had preeclampsia have a doubling of subsequent
ischaemic heart disease probably related to underlying vascular
pathology. This risk is greater the more growth restricted and
premature her baby is. At the post-natal visit future pregnancies
should be discussed as well as the need for screening for hypertension
in later life.
MAGNESIUM SULPHATE
Historic Perspective
Magnesium sulphate use was first reported in the early 1900s for
control of tetanic convulsions (Alton & Lincoln, 1925). Shortly
thereafter, Lazard reported use of magnesium sulphate for control of
eclamptic convulsions with associated fivefold (30% to 5.8%) reduction
of maternal mortality. Magnesium sulphate therapy was heralded as an
improvement on the previous therapeutic measures for eclampsia: enemas,
castor oil, and phlebotomy (Lazard, 1925). Magnesium sulphate therapy
was adopted for treatment of eclamptic convulsions from observational
studies and anecdotal experience. As a natural extension to its use for
eclamptic seizures, magnesium sulphate was adapted for prophylaxis of
seizures in women with severe preeclampsia; however, there is no
systematic, controlled evidence that magnesium sulphate prevents
progression to eclampsia.
The modern obstetric use of magnesium sulphate therapy for preeclampsia
or eclampsia is credited to Pritchard, who popularized the
1intramuscular route of administration of magnesium sulphate (10 g load
followed by 5 g every 4 hours) (Pritchard, 1955). Continuous
intravenous infusion was recommended by Zuspan (4 g load followed by 1
g/hour) (Zuspan, 1966) and subsequently modified by Sibai (6 g load
followed by 2 g/hour) (Sibai, 1990). Pritchard identified appropriate
serum levels of magnesium for treatment of eclamptic convulsions as
3.5–7 meq/L, corresponding to 4.2– 8.4 mg/dL (Pritchard, 1955).
Although there is decreased incidence of seizures in magnesium-treated
women (Lucas et al, 1995), no study has ever correlated explicit serum
levels of magnesium with elimination of seizure activity analogous to
the use of minimal inhibitory concentration and selection of
antimicrobial agents. The concept of appropriate magnesium levels is
from the clinical experience of Pritchard that most eclamptic seizures
were successfully treated when the above magnesium levels were attained
(Pritchard, 1955). 
Pritchard noted that higher plasma levels of magnesium were needed for
arrest of convulsions rather than for seizure prophylaxis; however, the
levels suggested by Pritchard for prophylaxis were similar to those
used for seizure therapy. Despite this practice, the actual magnesium
level needed for prophylaxis has never been established.
Pharmacology
For many years, the Zuspan regimen was used for prophylaxis and therapy
of seizures. Sibai et al (1981) noted failures with this magnesium
sulphate regimen, thus evaluated 178 random magnesium levels from 120
women, obtained 2–48 hours following infusion of a 4 g intravenous
magnesium sulphate loading dose followed by maintenance doses of 1–3 g
per hour. Only 2 of 115 women receiving maintenance infusions of 1 g
per hour magnesium sulphate had magnesium levels between 4.8– 8.4 mg/dL
(recommended “therapeutic” range). Only 23 (51%) of 45 women receiving
maintenance infusions of 2 g per hour magnesium sulphate had serum
magnesium levels in the recommended range. All women receiving a
maintenance infusion of 3 g per hour magnesium sulphate had magnesium
levels within the recommended range. This study (Sibai et al, 1981)
altered clinical practice in the United States accordingly, changing
the maintenance magnesium sulphate infusion from 1 g per hour to 2 g
per hour.
Subsequently, Sibai (1990) studied the magnesium levels achieved with
varied doses of intravenous magnesium sulphate and recommended a 6 g
magnesium sulphate loading dose (producing serum magnesium levels
between 5–9 mg/dL) followed by 2 g/hour continuous magnesium sulfate
infusion with resultant magnesium levels between 4–8 mg/dL.
Mode of Action
Despite magnesium sulphate use for more than 70 years, its mechanism of
action for treatment and prophylaxis of preeclampsia or eclampsia
remains an enigma. For many years, the standard dose of magnesium
sulphate was 4 g intravenous loading dose followed by a maintenance
infusion of 1 g/hour in many obstetric units. As discussed earlier,
this dose was subsequently found to produce levels below 4.8 mg/dL in
the majority of women treated (Sibai et al, 1981). Despite recognition
of these insufficient levels and an increased in the maintenance dose
of magnesium sulphate therapy from 1 to 2 g/hour, the incidence of
eclampsia has not changed over the past 30 years (Sibai et al, 1981).
This raises the questions: Does magnesium sulphate therapy prevent
progression to eclampsia? or Is there a subset of preeclamptic women
who are destined to develop eclampsia despite prophylactic therapy?
Ideally, clinical or laboratory markers could be perfected to identify
impending eclampsia in women with severe preeclampsia. Roberts (1995)
suggested that the ideal management of women with preeclampsia would be
selective seizure prophylaxis for those women deemed to be at greatest
1risk of seizures. Does the efficacy of magnesium sulphate for seizure
prophylaxis or therapy vary according to the degree of cerebral
vasoconstriction in these women? Are there subgroups of women with
preeclampsia who will benefit from cerebral vasodilatation while for
other women such therapy would be detrimental? Future studies should
evaluate this disease progression and assess specific risk factors or
markers that would mandate or contraindicate magnesium sulphate seizure
prophylaxis.
Current evidence adds conflicting data about the mode or site of action
of magnesium sulphate. Sibai et al (1984) performed
electroencephalograms on 36 eclamptic and 14 preeclamptic magnesium
treated women. Twenty seven of the eclamptic women and seven of the
preeclamptic women had abnormal electroencephalograms despite
therapeutic magnesium levels (4.5–11 mg/dL). Two women with eclampsia
had clinical seizure activity during their postpartum
electroencephalograms despite magnesium levels of 9.6 and 11 mg/dL. It
was concluded that if magnesium suppresses seizure activity, the
mechanism is distinct from modification of the electroencephalogram,
refuting a direct action of magnesium sulphate on eclamptic seizures.
Adverse Effects and Safety
The use of magnesium sulphate is associated with a high rate of minor
side effects, such as feeling warm, flushed, nausea or vomiting, muscle
weakness, dizziness, and irritation at the site of injections. The
reported rates of these effects in randomized trials ranged from 15% to
67% (Magpie Trial, 2002; Belfort et al, 2003; Witlin et al, 1997).
These side effects were the most common reason for the woman’s request
to stop treatment early in the Magpie Trial. In addition, the use of
magnesium sulphate is associated with major side effects such as
respiratory depression and postpartum haemorrhage (2.4% vs 1.0%, P=
0.03) (Belfort et al, 2003).
 Life-threatening magnesium toxicity is extremely rare with correct
dosing and proper monitoring of the patient during magnesium sulphate
therapy. Nevertheless, maternal deaths from magnesium overdose have
been reported from the US (Pritchard et al, 1984) and from South Africa
(Richards et al, 1985). In addition, magnesium toxicity from overdose
nearly led to maternal deaths in 2 other reports (Sibai et al, 1981).
CHAPTER 3: OBJECTIVES, RESEARCH QUESTIONS, HYPOTHESIS, AND OPERATIONAL
DEFINITIONS
3.1 General Objective
     To evaluate the safety and effectiveness of using clinical
parameters to signal cessation of postpartum magnesium sulphate (MgSO4)
in patients with severe preeclampsia.
3.2 Specific objectives
3.2.1 To compare the outcomes of MgSO4 therapy as a postpartum seizures
prophylaxis for conventional 24 hours and early cessation based on
clinical parameters.
13.2.2 To determine the optimal duration of MgSO4 therapy in patient
with severe    preeclampsia.
3.3 Research Questions
Is there any difference in the outcome among postnatal mothers who
received MgSO4 for 24 hours and early cessation of MgSO4 based on
clinical parameters?
3.4 Research Hypothesis
There is no difference between using MgSO4 postpartum for 24 hours or
early cessation based on clinical parameters. 
3.5 Operational definitions
3.5.1 Hypertension
Hypertension in Pregnancy is defined as a systolic blood pressure (BP)
of 140mm Hg and/or a diastolic BP of 90 mmHg. An increase of 15 mmHg
and 30 mmHg of diastolic and systolic BP levels above baseline BP
respectively are no longer recognized as hypertension if absolute
values are below 140/90 mmHg. Nevertheless, this warrants close
observation, especially if proteinuria and hyperuricaemia are also
present. Korotkoff V should now be used as the cut-off point for
diastolic BP, and Korotkoff IV utilized only when Korotkoff V is
absent.
3.5.2 Proteinuria 
Significant proteinuria in pregnancy is defined as 300 mg protein in a
24 hour urine sample, or a spot urine protein-creatinine ratio 30
mg/mmol.  If the dipstick is the only test available, 1+ (30 mg/dl) are
often, but not always,    associated with 300 mg/day proteinuria.
Significant proteinuria reflects advanced disease, associated with
poorer prognosis.
3.5.3 Classification
There are various classifications for Hypertension in Pregnancy. The
most recent is by the Australasian Society for the Study of
Hypertension in Pregnancy (ASSHP) and endorsed by the International
Society for the Study of Hypertension in Pregnancy (ISSHP) (Brown et
al, 2001).
 a). Preeclampsia/eclampsia: clinically diagnosed in the presence of de
novo hypertension    after gestational week 20, and one or more of the
following:
i. Significant proteinuria.
ii. Renal insufficiency: serum creatinine 90 ìmol/l or oliguria.
            iii. Liver disease: raised transaminases and/or severe
right upper
quadrant or epigastric pain.
iv. Neurological problems: convulsions (eclampsia),
hyperreflexia 
with clonus or severe headaches, persistent visual
disturbances (scotoma).
1v. Haematological disturbances: thrombocytopenia, coagulopathy,
haemolysis.
vi. Fetal growth restriction.
This is followed by normalisation of the BP by three months postpartum.
Oedema is no longer part of the definition of preeclampsia. Either
excessive weight gain or failure to gain weight in pregnancy may herald
the onset of preeclampsia.
b). Gestational hypertension: hypertension alone, detected for the
first time after 20 weeks pregnancy. The definition is changed to
“transient” when pressure normalizes postpartum.
c). Chronic hypertension: hypertension diagnosed prior to gestational
week 20; or presence of hypertension preconception, or de novo
hypertension in late gestation that fails to resolve postpartum. 
d). Preeclampsia superimposed on chronic hypertension:
This can be diagnosed by the appearance of any of the following in a
woman with chronic hypertension:
i) De novo proteinuria after gestational week 20
ii) A sudden increase in the severity of hypertension
iii) Appearance of features of preeclampsia-eclampsia, and
iv) A sudden increase in proteinuria in women who have
preexisting proteinuria early in gestation
(Reference : Clinical Practice Guidelines, MOH :Management of
Hypertension 3rd Edition,February 2008) .
CHAPTER FOUR: METHODOLOGY
4.1 Study design, Setting and Duration.
This study was a randomized controlled trial study with single blinded
trial. It was a study to compare the safety and effectiveness of giving
postpartum MgSO4 for 24 hours and early cessation based on clinical
parameters among postnatal mothers who received MgSO4 before delivery
in HRPZ11 and HUSM. Patients’ recruitment began from December 2009
until September 2010. 
4.2 Reference population
All postnatal mothers who received IV MgSO4 before delivery at Labour
Room HRPZII and Labour Room HUSM.
4.3 Source population / Sampling frame
All postnatal mothers who received IV MgSO4 before delivery at Labour
Room HRPZII and Labour Room HUSM from December 2009 until September
2010.
4.4 Inclusion criteria
 All patients with severe preeclampsia 
               BP = 160/110          and
               Proteinuria = 2+       and/ or
              Symptomatic (frontal headache, visual disturbance,
epigastric pain, nausea, vomiting)
 All severe preeclampsia superimposed on chronic hypertension
4.5 Exclusion criteria
1Mild Preeclampsia
Eclampsia
Underlying seizure disorder
4.6 Sampling method 
Block Randomization was used to determine treatment group
allocation.104 individuals randomized into two treatment groups of A
and B, in blocks of 4. Block of 4 would give 6 combinations of AABB,
ABAB, BBAA, BABA, ABBA, and BAAB. Every combination will be assigned a
number of 1, 2, 3, 4, 5 and 6 respectively. A series of random number
will be generated using table of random number (Appendix A). 26
appropriate consecutive numbers will be used to assign to list of 104
participants (i.e. 26 numbers x 4 blocks).
After completing randomization method as described above, a list of 104
participants will be generated with assigned randomized treatment group
(Appendix B). This list would determine which treatment group every
participant will be allocated to. Every participant recruited will be
placed in consecutive manner one after the other until 102 participants
were finally recruited. The total number of the participants recruited
in this study was 102.
STUDY PROTOCOL 
Figure 2 Flow chart of the study.
4.7 Sample size calculation
Objective 1:
     To compare the outcomes of giving MgSO4 as a postpartum seizures
prophylaxis for   conventional 24 hours and to stop MgSO4 based on
1clinical parameters
Comparing two proportion (Using PS software, Dupont + Plummer version
3.0.2)
We are planning a study of independent cases and controls with 1
control per case.  Prior data indicate that the failure rate among
controls is 0.02 (Ascarelli et al, 1998).  
If the true failure rate for experimental subjects is 0.2, we will need
to study 46 experimental subjects and 46 control subjects to be able to
reject the null hypothesis that the failure rates for experimental and
control subjects are equal with probability (power) 0.8. 
The Type I error probability associated with this test of this null
hypothesis is 0.05.  
I will choose sample size as 92 in view of limitation with time and
power.
With the anticipation of non-response, I will take additional 10%, so
that the total sample will be 102 
Objective 2:
     To determine the optimal duration of MgSO4 therapy in pregnant
women with hypertensive disorders
Use PS software (Dupont & Plummer version 3.0.2) to calculate sample
size based on comparing 2 means
With 80% power and alpha 0.05
SD = 8.5 hours (Fontenot et al, 2005)
To detect the difference of 4 hours
Therefore, need 79 participants in each study group ( with 10%
non-response) 
4.8 Participants’ recruitment 
This randomized controlled trial study was conducted at the labour room
HRPZII and HUSM between December 2009 and September 2010 (10 months).
The protocol was approved by Ethic Committee Ministry of Health and
HUSM. All patients with the diagnosis of severe preeclampsia at the
time of delivery were invited to participate. Patients were classified
according to the Ministry of Health Hypertension Guideline.  Patients
with mild preeclampsia, eclampsia and a history of seizure disorder
were excluded from this investigation.
All patients received intravenous magnesium sulphate as a seizure
prophylaxis before delivery period consisting of a 4-g loading dose and
a 1-g per hour maintenance dose. After delivery, they were randomized
into two groups, intervention and control group. The control group
received a 1-g per hour maintenance dose for 24 hours postpartum. The
intervention group received a 1-g per hour maintenance dose for 12
hours postpartum. Once minimum therapy had been delivered, 4 clinical
parameters were used to determine whether intravenous magnesium
sulphate could be discontinued. 
These criteria included; absence of persistent headache, visual
changes, and epigastric pain; greater than 50% of the hourly postpartum
blood pressures less than 150mmHg systolic and less than 100mmHg
diastolic (including the hour immediately before medication
discontinuation); no indication for acute antihypertensive therapy
within the preceding 2 hours (systolic blood pressure greater than or
equal to 160 mm Hg or diastolic blood pressure greater than or equal to
110 mm Hg); and spontaneous diuresis of more than 25 mL per hour for 2
